表紙
市場調査レポート

世界のフィブリノゲン市場および製品パイプライン分析

Analysis of the Global Fibrinogen Market and Product Pipeline

発行 Frost & Sullivan 商品コード 346559
出版日 ページ情報 英文 54 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.16円で換算しております。
Back to Top
世界のフィブリノゲン市場および製品パイプライン分析 Analysis of the Global Fibrinogen Market and Product Pipeline
出版日: 2015年12月08日 ページ情報: 英文 54 Pages
概要

フィブリノゲンの需要拡大と、スプレイ、パッチなどの革新的デリバリーシステムの開発により、世界のフィブリノゲン市場の拡大が加速しています。

当レポートでは、世界のフィブリノゲン市場について調査し、市場の現状と2020年までの成長見通し、競合環境、パイプラインおよび治験動向などをまとめています。

第1章 エグゼクティブサマリー

第2章 調査方法と調査範囲

第3章 市場背景

  • 市場概要:イントロダクション
  • 血漿生産
  • 市場セグメンテーション
  • 血漿市場シェア
  • フィブリノゲン生産
  • 収益予測
  • 考察
  • サプライチェーンと流通網

第4章 競合環境:ヒト用フィブリノゲン(上市済みおよびパイプライン製品)

第5章 極めて重要な第3相治験

  • フィブリノゲン市場:継続中/最近完了した治験
  • 注目の主要製品サマリー
  • 主なイベントスケジュール:製品上市

第6章 製品ダッシュボード(上市済みおよび第3相製品)

  • Haemocomplettan/RiaSTAP
  • Clottafact
  • Octafibrin
  • Artiss
  • Evarrest
  • Raplixa
  • FS Grifols

第7章 結論

  • 結論
  • 法的免責事項

第8章 Frost & SUllicanストーリー

目次
Product Code: MB93-52

Launch of Topical and Ready-to-Use Fibrin Sealants Impetus to Growth

The increased demand for fibrinogen and the development of innovative delivery systems such as sprays and patches are fuelling the growth of the fibrinogen market. This research service provides a detailed assessment of the global fibrinogen market, covering the current market scenario and growth prospects for the period 2015-2020. Both marketed and pipeline products are segmented based on their therapeutic uses, namely, deficiency therapy and operative care. An elaborate discussion on clinical trial timelines and results, along with historical and projected launch timelines, has been provided. The study also discusses key companies such as CSL Behring, LFB, Baxter Healthcare, Takeda, Grifols, and Octapharma.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Executive Summary-Key Findings
  • 2. Executive Summary-Key Findings (continued)
  • 3. Key Trends
  • 4. Companies to Watch

2. METHODOLOGY AND SCOPE

Methodology and Scope

  • 1. Methodology and Scope

3. MARKET BACKGROUND

Market Background

  • 1. Market Overview-Introduction
  • 2. Market Overview-Blood Plasma Production
  • 3. Market Segmentation
  • 4. Blood Plasma Market Share
  • 5. Fibrinogen Production
  • 6. Revenue Forecast
  • 7. Revenue Forecast Discussion
  • 8. Supply Chain and Distribution Network
  • 9. Supply Chain and Distribution Network (continued)

4. COMPETITIVE LANDSCAPE-HUMAN FIBRINOGEN (MARKETED AND PIPELINE PRODUCTS)

Competitive Landscape-Human Fibrinogen (Marketed and Pipeline Products)

  • 1. Competitive Landscape-Marketed and Pipeline Products
  • 2. Competitive Landscape Overview
  • 3. Marketed Products-Deficiency and Other Therapies
  • 4. Pipeline Products-Deficiency and Other Therapies
  • 5. Marketed Products-Operative Care
  • 6. Marketed Products-Operative Care (continued)
  • 7. Pipeline Products-Operative Care

5. PIVOTAL PHASE 3 TRIALS

Pivotal Phase 3 Trials

  • 1. Fibrinogen Market-Major On-going/Recently Completed Clinical Trials
  • 2. Fibrinogen Market-Major On-going/Recently Completed Clinical Trials (continued)
  • 3. Fibrinogen Market-Major On-going/Recently Completed Clinical Trials (continued)
  • 4. Summary of Key Products to Watch
  • 5. Summary of Key Products to Watch (continued)
  • 6. Timeline of Key Events-Launch of Products

6. PRODUCT DASHBOARD (KEY MARKETED AND PHASE 3 PRODUCTS)

Product Dashboard (Key Marketed and Phase 3 Products)

  • 1. Product Dashboard-Haemocomplettan/RiaSTAP (CSL Behring)
  • 2. Product Dashboard-Clottafact (LFB)
  • 3. Product Dashboard-Octafibrin (Octapharma)
  • 4. Product Dashboard-Artiss (Baxter Healthcare)
  • 5. Product Dashboard-Evarrest (Ethicon)
  • 6. Product Dashboard-Raplixa (The Medicines Company)
  • 7. Product Dashboard-FS Grifols (Grifols)

7. CONCLUSIONS

Conclusions

  • 1. Conclusions
  • 2. Legal Disclaimer

8. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition-Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
Back to Top